Kardigan, Inc.(KARD)

Biotechnology · Princeton, NJ

$14.07-1.17 (-7.68%)

Delayed quote: Oct 6, 2026, 12:50 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T16:52:06.843Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:52:06.843Z.

Quote observation: 2026-10-06T16:50:02.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,257,001,432
Total debt · period ending 2026-06-30: 13,347,000
Cash · period ending 2026-06-30: 384,005,000
TTM free cash flow · period ending 2026-06-30: N/A

FMP input reference: 6dd2a4984e4340952b62e9ecd156f35eed99e3c78779d37ae6f95d3f5c845125

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KARD EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

KARD Competitors' EV/FCF Ratio

KARD

Kardigan, Inc.

Current

Market Cap

$1.26B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORIC

ORIC Pharmaceuticals, Inc.

vs KARD

Market Cap

$1.24B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMDA

Omada Health

vs KARD

Market Cap

$1.23B

EV/FCF Ratio

50.15x

TTM Avg

50.12x

3Y Avg

50.12x

5Y Avg

50.12x

CRON

Cronos Group Inc.

vs KARD

Market Cap

$1.22B

EV/FCF Ratio

15.21x

TTM Avg

580.30x

3Y Avg

501.54x

5Y Avg

501.54x

MNKD

MannKind Corporation

vs KARD

Market Cap

$1.22B

EV/FCF Ratio

N/A

TTM Avg

74.41x

3Y Avg

125.98x

5Y Avg

125.98x

INNV

Innovage Holding Corp.

vs KARD

Market Cap

$1.21B

EV/FCF Ratio

23.81x

TTM Avg

28.78x

3Y Avg

30.44x

5Y Avg

41.95x

DRTS

Alpha Tau Medical Ltd

vs KARD

Market Cap

$1.32B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs KARD

Market Cap

$1.34B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DMRA

Damora Therapeutics, Inc.

vs KARD

Market Cap

$1.17B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMER

Omeros Corporation

vs KARD

Market Cap

$1.35B

EV/FCF Ratio

N/A

TTM Avg

6.97x

3Y Avg

6.99x

5Y Avg

6.99x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Kardigan, Inc. (KARD)	$1.26B	N/A	N/A	N/A	N/A
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.24B	N/A	N/A	N/A	N/A
Omada Health (OMDA)vs ›	$1.23B	50.15x	50.12x	50.12x	50.12x
Cronos Group Inc. (CRON)vs ›	$1.22B	15.21x	580.30x	501.54x	501.54x
MannKind Corporation (MNKD)vs ›	$1.22B	N/A	74.41x	125.98x	125.98x
Innovage Holding Corp. (INNV)vs ›	$1.21B	23.81x	28.78x	30.44x	41.95x
Alpha Tau Medical Ltd (DRTS)vs ›	$1.32B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.34B	N/A	N/A	N/A	N/A
Damora Therapeutics, Inc. (DMRA)vs ›	$1.17B	N/A	N/A	N/A	N/A
Omeros Corporation (OMER)vs ›	$1.35B	N/A	6.97x	6.99x	6.99x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

KARD EV/FCF Ratio Metrics

KARD Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics